Scarica l'app Stockscreener
75.64
0.27%
0.20
Dopo l'orario di chiusura:
75.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$75.44
Aprire:
$75.83
Volume 24 ore:
886.80K
Relative Volume:
0.59
Capitalizzazione di mercato:
$6.07B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-12.73
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-2.09%
1M Prestazione:
+0.92%
6M Prestazione:
+48.37%
1 anno Prestazione:
+59.71%
Intervallo 1D:
$74.50
$76.16
Intervallo di 1 settimana:
$73.09
$78.77
Portata 52W:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
75.64 | 6.06B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Squarepoint Ops LLC Grows Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Armistice Capital LLC Has $231.28 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - BioSpace
Marshall Wace LLP Reduces Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stock Position Raised by Hood River Capital Management LLC - MarketBeat
Emma Reeve Sells 733 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Can PTC Therapeutics Inc. (BH3) stock sustain breakout momentumShare Buyback & Weekly Watchlist for Consistent Profits - Newser
Russell Investments Group Ltd. Buys 118,105 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
How higher bond yields impact PTC Therapeutics Inc. (BH3) stock2025 Price Action Summary & Step-by-Step Trade Execution Guides - Newser
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $271,051.96 in Stock - MarketBeat
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - AOL.com
Why PTC Therapeutics Inc. stock could rally in 2025Inflation Watch & Target Return Focused Picks - Newser
Will PTC Therapeutics Inc. (BH3) stock outperform global peers2025 Analyst Calls & Entry Point Strategy Guides - Newser
PTC Therapeutics (NASDAQ:PTCT) Shares Down 5.6%Time to Sell? - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Panagora Asset Management Inc. Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT): Revisiting Valuation After Strong Multi‑Year Share Price Gains - Yahoo Finance
PTC Therapeutics (PTCT) Gets a Sell from Goldman Sachs - The Globe and Mail
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - Nasdaq
PTC Therapeutics downgraded at RBC as Sephience sales priced in - MSN
PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says - marketscreener.com
Prudential Financial Inc. Has $4.12 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics stock price target raised to $55 from $50 at Goldman Sachs - Investing.com UK
Legal & General Group Plc Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Transcript : PTC Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - marketscreener.com
Can PTC Therapeutics Inc. (BH3) stock retain market dominance2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
How PTC Therapeutics Inc. (BH3) stock moves on employment dataQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
Is PTC Therapeutics Inc. stock a buy for dividend growth2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
Why PTC Therapeutics Inc stock could rally in 2025Weekly Earnings Recap & Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividendsPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Finviz
PTC Therapeutics Shares Drop After RBC Downgrade - marketscreener.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in (PTCT:NASDAQ) - Seeking Alpha
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - The Manila Times
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
PTC Therapeutics stock downgraded by RBC Capital as shares near fair value - Investing.com Canada
RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82 - marketscreener.com
(PTCT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Elo Mutual Pension Insurance Co Makes New $689,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation - Yahoo Finance
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Globe and Mail
Advantage Alpha Capital Partners LP Invests $204,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ptc Therapeutics Inc Azioni (PTCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reeve Emma | Director |
Dec 03 '25 |
Sale |
78.62 |
733 |
57,628 |
6,666 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Dec 02 '25 |
Sale |
79.07 |
3,428 |
271,052 |
349,964 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):